The world is entering a new phase of psychiatric treatments.
After the psychotherapy and medical treatment phases in the last century, we are at the start of the phase where we use drugs to assist and empower psychotherapeutic processes.
The origins of this exciting new development are the massive growth of neuropsychopharmacology, particularly in relation to the use of psychedelics (e.g. LSD, Psilocybin) and entactogens (e.g. MDMA).
New research on the impact of these drugs on brain functions show clear impacts on brain processes that contribute to maladaptive behavioural processes.
Parallel research has shown efficacy for psilocybin and MDMA in disorders such as resistant depression and PTSD.
In this first ever live Drug Science podcast recording, Professor Nutt and invted guests will cover these remarkable new developments and show how they may be used more broadly in psychiatry/psychotherapy in the future.
Speakers to include:
Prof David Nutt
This is a Drug Science Community exclusive event. Our community members support our work with £10/month or more. As a community member you will access opportunities to become more deeply engaged in our work through exclusive events, content, and access to our expert committee.